These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 36109788)

  • 1. Rapamycin and inulin for booster vaccine response stimulation (RIVASTIM)-rapamycin: study protocol for a randomised, controlled trial of immunosuppression modification with rapamycin to improve SARS-CoV-2 vaccine response in kidney transplant recipients.
    Tunbridge M; Perkins GB; Singer J; Salehi T; Ying T; Grubor-Bauk B; Barry S; Sim B; Hissaria P; Chadban SJ; Coates PT
    Trials; 2022 Sep; 23(1):780. PubMed ID: 36109788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapamycin and inulin for third-dose vaccine response stimulation (RIVASTIM): Inulin - study protocol for a pilot, multicentre, randomised, double-blinded, controlled trial of dietary inulin to improve SARS-CoV-2 vaccine response in kidney transplant recipients.
    Singer J; Tunbridge M; Perkins GB; Salehi T; Ying T; Wu H; Coates PT; Chadban SJ
    BMJ Open; 2022 Dec; 12(12):e062747. PubMed ID: 36456021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protocol for SARS-CoV-2 post-vaccine surveillance study in Australian adults and children with cancer: an observational study of safety and serological and immunological response to SARS-CoV-2 vaccination (SerOzNET).
    Body A; Ahern E; Lal L; Gillett K; Abdulla H; Opat S; O'Brien T; Downie P; Turville S; Munier CML; Smith C; MacIntyre CR; Segelov E
    BMC Infect Dis; 2022 Jan; 22(1):70. PubMed ID: 35057745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunosuppression reduction when administering a booster dose of the BNT162b2 mRNA SARS-CoV-2 vaccine in kidney transplant recipients without adequate humoral response following two vaccine doses: protocol for a randomised controlled trial (BECAME study).
    Yahav D; Rozen-Zvi B; Mashraki T; Atamna A; Ben-Zvi H; Bar-Haim E; Rahamimov R
    BMJ Open; 2021 Oct; 11(10):e055611. PubMed ID: 34635537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humoral Response After SARS-CoV-2 Vaccination in Kidney Transplant Recipients: Role of Immunosuppression Therapy.
    López V; Polo C; Schuldt R; Vázquez T; Gutiérrez-Vílchez E; Moliz C; Hernández D
    Transplant Proc; 2022 Nov; 54(9):2454-2456. PubMed ID: 36273957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunologic response to SARS-CoV-2 mRNA vaccination in pediatric kidney transplant recipients.
    Kermond RF; Ozimek-Kulik JE; Kim S; Alexander SI; Hahn D; Kesson A; Wood N; McCarthy HJ; Durkan AM
    Pediatr Nephrol; 2023 Mar; 38(3):859-866. PubMed ID: 35833990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temporary reduction of immunosuppression enhances production of anti-S antibody against severe acute respiratory syndrome coronavirus 2 after vaccination in kidney transplant recipients.
    Miura M; Fukumoto M; Komatsu N; Shuto R; Harada H; Sasaki H
    Int J Urol; 2022 Dec; 29(12):1505-1510. PubMed ID: 36070502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dietary Inulin to Improve SARS-CoV-2 Vaccine Response in Kidney Transplant Recipients: The RIVASTIM-Inulin Randomised Controlled Trial.
    Singer J; Tunbridge MJ; Shi B; Perkins GB; Chai CS; Salehi T; Sim BZ; Kireta S; Johnston JK; Akerman A; Milogiannakis V; Aggarwal A; Turville S; Hissaria P; Ying T; Wu H; Grubor-Bauk B; Coates PT; Chadban SJ
    Vaccines (Basel); 2024 Jun; 12(6):. PubMed ID: 38932337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of one and two booster doses of SARS-CoV-2 mRNA vaccines in kidney transplant recipients: A randomized clinical trial.
    Drenko P; Kacer M; Kielberger L; Vlas T; Topolcan O; Kucera R; Reischig T
    Transpl Infect Dis; 2023 Oct; 25(5):e14150. PubMed ID: 37724748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serological Response and Clinical Protection of Anti-SARS-CoV-2 Vaccination and the Role of Immunosuppressive Drugs in a Cohort of Kidney Transplant Patients.
    Biagio P; Rosa C; Nicola SM; Fabrizio S; Amerigo P; Giulia Z; Riccardo S; Riccardo V; Paolo R; Lorenzo S; Ivan G; Federico Ii Covid Team
    Viruses; 2022 Sep; 14(9):. PubMed ID: 36146758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bringing optimised COVID-19 vaccine schedules to immunocompromised populations (BOOST-IC): study protocol for an adaptive randomised controlled clinical trial.
    Griffin DWJ; Dymock M; Wong G; Morrissey CO; Lewin SR; Cheng AC; Howard K; Marsh JA; Subbarao K; Hagenauer M; Roney J; Cunningham A; Snelling T; McMahon JH
    Trials; 2024 Jul; 25(1):485. PubMed ID: 39020446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients: A Randomized Clinical Trial.
    Reindl-Schwaighofer R; Heinzel A; Mayrdorfer M; Jabbour R; Hofbauer TM; Merrelaar A; Eder M; Regele F; Doberer K; Spechtl P; Aschauer C; Koblischke M; Paschen C; Eskandary F; Hu K; Öhler B; Bhandal A; Kleibenböck S; Jagoditsch RI; Reiskopf B; Heger F; Bond G; Böhmig GA; Strassl R; Weseslindtner L; Indra A; Aberle JH; Binder M; Oberbauer R
    JAMA Intern Med; 2022 Feb; 182(2):165-171. PubMed ID: 34928302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
    Zhu F; Zhuang C; Chu K; Zhang L; Zhao H; Huang S; Su Y; Lin H; Yang C; Jiang H; Zang X; Liu D; Pan H; Hu Y; Liu X; Chen Q; Song Q; Quan J; Huang Z; Zhong G; Chen J; Han J; Sun H; Cui L; Li J; Chen Y; Zhang T; Ye X; Li C; Wu T; Zhang J; Xia NS
    Lancet Respir Med; 2022 Aug; 10(8):749-760. PubMed ID: 35644168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of mTOR inhibitor in the cellular and humoral immune response to a booster dose of SARS-CoV-2 mRNA-1273 vaccine in kidney transplant recipients.
    Pérez-Flores I; Juarez I; Aiffil Meneses AS; Lopez-Gomez A; Romero NC; Rodriguez-Cubillo B; Moreno de la Higuera MA; Peix-Jiménez B; Gonzalez-Garcia R; Baos-Muñoz E; Vilela AA; Gómez Del Moral M; Martínez-Naves E; Sanchez-Fructuoso AI
    Front Immunol; 2023; 14():1111569. PubMed ID: 36817489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study.
    Rozen-Zvi B; Yahav D; Agur T; Zingerman B; Ben-Zvi H; Atamna A; Tau N; Mashraki T; Nesher E; Rahamimov R
    Clin Microbiol Infect; 2021 Aug; 27(8):1173.e1-1173.e4. PubMed ID: 33957273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temporary antimetabolite treatment hold boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients.
    Schrezenmeier E; Rincon-Arevalo H; Jens A; Stefanski AL; Hammett C; Osmanodja B; Koch N; Zukunft B; Beck J; Oellerich M; Proß V; Stahl C; Choi M; Bachmann F; Liefeldt L; Glander P; Schütz E; Bornemann-Kolatzki K; López Del Moral C; Schrezenmeier H; Ludwig C; Jahrsdörfer B; Eckardt KU; Lachmann N; Kotsch K; Dörner T; Halleck F; Sattler A; Budde K
    JCI Insight; 2022 May; 7(9):. PubMed ID: 35349490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk Factors for Weak Antibody Response of SARS-CoV-2 Vaccine in Adult Solid Organ Transplant Recipients: A Systemic Review and Meta-Analysis.
    Zong K; Peng D; Yang H; Huang Z; Luo Y; Wang Y; Xiang S; Li T; Mou T; Wu Z
    Front Immunol; 2022; 13():888385. PubMed ID: 35774786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low switched memory B cells are associated with no humoral response after SARS-CoV-2 vaccine boosters in kidney transplant recipients.
    Seija M; García-Luna J; Rammauro F; Brugnini A; Trías N; Astesiano R; Santiago J; Orihuela N; Zulberti C; Machado D; Recalde C; Yandián F; Guerisoli A; Noboa J; Orihuela S; Curi L; Bugstaller E; Noboa O; Nin M; Bianchi S; Tiscornia A; Lens D
    Front Immunol; 2023; 14():1202630. PubMed ID: 37942335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.